Preimplantation Genetic Testing (PGT)
We provide microarray based PGT-A (previously known as preimplantation aneuploidy screening) and PGT-SR. PGT is the process of analyzing the chromosomes of embryos conceived by IVF or ICSI for common abnormalities. Chromosomal abnormalities are a major cause of the failure of embryos to implant and of miscarriages.
PGT-A is used to detect numerical chromosomal abnormalities such as trisomy and monosomy. Embryos with numerical abnormalities result in fetuses with an abnormal number of chromosomes such as trisomy 21 (Down syndrome).
PGT-SR is utilized to identify genomic imbalances that result from parental structural chromosomal rearrangement such as translocations, inversions, deletions, and duplications affecting a portion of chromosome. Carriers of structural chromosomal rearrangements are at high risk to produce embryos with extra or missing chromosome segments. A consult with the laboratory personnel is recommended for PGT-SR because patient-specific chromosomal rearrangement information is used to determine optimal technique and protocol.
Clinical indication for PGT-A and PGT-SR
- Advanced maternal age
- History of recurrent miscarriages
- Infertility and unsuccessful history of IVF
- Family history of chromosome problems
Four to eight cell trophectoderm biopsy will be performed on day 5-7 of embryo development. Microarray analysis will be conducted using amplified DNA samples.
Please contact the IVF laboratory directly for details.
Platform For PGT Array Analysis
We perform array CGH using an Agilent platform.
Benefits of PGT Testing
PGT will greatly increase the odds of selecting chromosomally normal embryos and allows your physician to use a single embryo to implant. Transfer of a single normal embryo improves the odds of implantation and significantly decreases the risk of having twin or triplet pregnancies.